Citi lowered the firm’s price target on BioNTech (BNTX) to $130 from $145 and keeps a Buy rating on the shares. The departures of the company’s co-founders is a surprise but the share selloff offers a good entry point, the analyst tells investors in a research note. Citi says BioNTech’s pipeline has multiple Phase 3 opportunities.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
Disclaimer & DisclosureReport an Issue
| Nov-12 | |
| Nov-12 | |
| Nov-03 | |
| Nov-03 | |
| Nov-03 | |
| Oct-26 | |
| Oct-26 | |
| Oct-25 | |
| Oct-23 | |
| Oct-22 | |
| Oct-20 | |
| Oct-19 | |
| Oct-13 | |
| Oct-13 | |
| Oct-13 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite